The ODX assay was first covered under Medicare in 2006 and added to guidelines for treatment of node‐negative HR‐positive, HER2‐negative breast cancers by the American Society of Clinical Oncology and National Comprehensive Cancer Network in 2007 and early 2008, respectively. The gene discussed is ERBB2; the disease is breast cancer.